Draft Guidance: Responding to FDA Form 483 Observations for Drug Manufacturers

Detected March 7th, 2026

Summary

The FDA has issued draft guidance for drug manufacturers on how to respond to observations noted on FDA Form 483 following CGMP inspections. This guidance is intended to assist domestic and foreign manufacturers in assessing conformity with CGMP requirements.

View original document View source feed page

What changed

The FDA has released a draft guidance document titled "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection." This guidance is specifically for foreign and domestic human and animal drug manufacturing establishments inspected by the FDA, whose drugs are regulated by CDER, CBER, and CVM. Its purpose is to help manufacturers who choose to respond to FDA Form 483 observations after an inspection, aiding them in demonstrating conformity with current good manufacturing practice (CGMP) requirements.

While this is a draft guidance and therefore non-binding, manufacturers should review it to understand the FDA's expectations regarding responses to inspectional observations. The document is open for public comment, with comments to be submitted via the provided docket number. Although no specific compliance deadline is mentioned for adopting the guidance, manufacturers should consider its recommendations when formulating their responses to Form 483 observations to ensure continued compliance with CGMP standards.

What to do next

Review the draft guidance on responding to FDA Form 483 observations.
Consider submitting comments on the draft guidance via the provided docket number.
Update internal procedures for responding to FDA Form 483 observations based on the guidance's recommendations.

Source document (simplified)

Search for FDA
Guidance Documents

Docket Number: FDA-2025-D-1504 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Center for Veterinary Medicine Office of Inspections and Investigations The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” This guidance is intended for foreign and domestic human and animal drug manufacturing establishments inspected by FDA whose drugs are regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Veterinary Medicine (CVM). The purpose of this guidance is to assist manufacturers who choose to respond to FDA when they receive an FDA Form 483 Inspectional Observations (FDA 483) at the conclusion of a drug inspection to assess conformity with current good manufacturing practice (CGMP) requirements.